2021 the best year ever for our shareholders, our customers, and our patients" stated by the company
1. Nutra Pharma owns over 20 patents and trademarks as well as 119 internet domains.
2. These patents are built around their development of treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenoleukodystrophy(ALS), Adrenomyeloneuropathy(AMN), Rheumatoid Arthritis (RA), Pain, and Myasthenia Gravis (MG).
3. Nutra Pharma is already generating revenue with their Nyloxin®, Pet Pain-Away, and Equine Pain-Away in the over-the-counter pain management market, selling on different platforms such as Amazon, Walmart, and etc. They are selling worldwide in India as well.
4. Already granted Orphan Drug Status on their lead drug RPI-78M for treating Multiple Sclerosis in children.
5. All drugs completed Phase I trial and are ready for next phases II/III.
6. They have been working with private laboratories and governmental agencies to move forward their Nerve Agent Countermeasures and technology. Government grants and contracts are coming as stated in the shareholders letter by company.
7. Research partnership/joint ventures and funding to be announced regarding their lead drug RPI-78M for Multiple Sclerosis, HIV, ALS/AMN
8. In-house manufacturing of drug products including the future productions of RPI-78M. Turning into a cGMP manufacturing facility where the company will be able to make drugs for other drug companies.
9. Laboratory Upgrades, Certifications, and Expansions for the upcoming MS trials and the validation of company's nerve agent counter-measure.
10. Company regaining SEC compliance. Going for PINK and OTCQB status.
Going current, renewing all patents and trademarks. Hired the best SEC lawyers, auditors, and IP attorneys. All toxic notes paid. BIG Things coming!
See below:
Throughout 2021, we expect to continue actively marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away. We are currently working to begin a broad retail rollout that follows our acceptance at Walmart.com. These sales will bring in the revenue that will bring the company to profitability as well as provide the financing for the proposed clinical studies.
In 2021, we plan to begin working with joint venture partners to begin clinical trials with our Multiple Sclerosis (MS) drug, RPI-78M under our Orphan designation for pediatric MS. The Orphan status of the drug will allow for faster, less expensive trials as we lay the groundwork for the eventual drug production and trial protocol development. It is our goal to complete the Phase I/II trials in pediatric MS over the next 18-24 months and then either move into Phase III trials or seek a licensing partner.
We also plan to move forward with our work in nerve agent counter-measures and are filing for several grants with US governmental agencies to fund that work.
We believe that we have set the path for a bright future starting with 2021. Sales growth and marketing expansion will allow for a better market for our products and services. Marketing partnerships will bring in strategic investors with a vested interest in the future of our Company.
This will make 2021 our best year ever – for our shareholders, our customers and our patients.
Here is what Deitsch the CEO has done for NPHC in 19 years:
Added Many patents and trademarks to Nutra's portfolio
News 
Market Data 
Discover 
